View in EDS HTML Full Text PDF Full Text

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.

Saved in:
Bibliographic Details
Title: Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Authors: Shimoda Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tatyoshi@ncc.go.jp.; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tatyoshi@ncc.go.jp., Miyakoshi J; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Torasawa M; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Tateishi A; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Matsumoto Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Masuda K; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Shinno Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Okuma Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Goto Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Horinouchi H; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Yamamoto N; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan., Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Aug; Vol. 72 (8), pp. 2613-2621. Date of Electronic Publication: 2023 Apr 16.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37062033
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shimoda+Y%22">Shimoda Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Yoshida+T%22">Yoshida T</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tatyoshi@ncc.go.jp.; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tatyoshi@ncc.go.jp.<br /><searchLink fieldCode="AU" term="%22Miyakoshi+J%22">Miyakoshi J</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Torasawa+M%22">Torasawa M</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Tateishi+A%22">Tateishi A</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Matsumoto+Y%22">Matsumoto Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Masuda+K%22">Masuda K</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Shinno+Y%22">Shinno Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Okuma+Y%22">Okuma Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Goto+Y%22">Goto Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Horinouchi+H%22">Horinouchi H</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Yamamoto+N%22">Yamamoto N</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.<br /><searchLink fieldCode="AU" term="%22Ohe+Y%22">Ohe Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2023 Aug; Vol. 72 (8), pp. 2613-2621. <i>Date of Electronic Publication: </i>2023 Apr 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37062033
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-023-03429-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2613
    Titles:
      – TitleFull: Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shimoda Y
      – PersonEntity:
          Name:
            NameFull: Yoshida T
      – PersonEntity:
          Name:
            NameFull: Miyakoshi J
      – PersonEntity:
          Name:
            NameFull: Torasawa M
      – PersonEntity:
          Name:
            NameFull: Tateishi A
      – PersonEntity:
          Name:
            NameFull: Matsumoto Y
      – PersonEntity:
          Name:
            NameFull: Masuda K
      – PersonEntity:
          Name:
            NameFull: Shinno Y
      – PersonEntity:
          Name:
            NameFull: Okuma Y
      – PersonEntity:
          Name:
            NameFull: Goto Y
      – PersonEntity:
          Name:
            NameFull: Horinouchi H
      – PersonEntity:
          Name:
            NameFull: Yamamoto N
      – PersonEntity:
          Name:
            NameFull: Ohe Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2023 Aug
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 72
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1